Clinical Trials

Inclusion Criteria:

• Diagnosis of Chronic Hypersensitivity Pneumonitis (CHP) defined from the first instance in which a patient was informed of having CHP for at least 3 months.
• Age 18 through 85 years.
• Diagnosis of CHP by HRCT:
  • Typical CHP: Evidence of lung fibrosis (reticular abnormality and/or, traction bronchiectasis and/or, architectural distortion, and/or honeycombing), lack of features suggesting an alternative diagnosis and one or more of the following:
    • Profuse poorly defined centrilobular nodules of ground-glass opacity affecting all lung zones;
    • Inspiratory mosaic attenuation with three-density sign.
  • Compatible CHP*: Evidence of lung fibrosis (as above) lack of features suggesting an alternative diagnosis and one or more of the following:
    • Patchy or diffuse ground-glass opacity;
    • Patchy, non-profuse centrilobular nodules of ground-glass attenuation;
    • Mosaic attenuation and lobular air-trapping that do not meet criteria for typical fibrotic HP.

* These patients are required to have a known or indeterminate (suggestive) antigen exposure and/or BAL lymphocytosis (≥ 20%) and/or lung histology consistent with HP (e.g., transbronchial biopsies demonstrating non-necrotizing granuloma(s) or lymphocytosis and/or wedge biopsy or cryobiopsy with a typical, compatible or indeterminate pattern for HP).

•  
• Indeterminate CHP**:  CT signs of fibrosis without other features suggestive of HP.

** These patients are required to have a known or indeterminate (suggestive) antigen exposure and/or BAL lymphocytosis (≥ 20%) and/or lung histology consistent with HP (e.g., transbronchial biopsies demonstrating non-necrotizing granuloma(s) or lymphocytosis and/or wedge biopsy or cryobiopsy with a typical, compatible or indeterminate pattern for HP).

• Able to understand and sign a written informed consent form.
• Able to understand the importance of adherence to the study protocol and willing to follow all study requirements (e.g., completing procedures such as 6-min walk and questionnaires).

Exclusion Criteria:

• Not a suitable candidate for enrollment or unlikely to comply with the requirements of this study (e.g., unstable or deteriorating cardiac disease such as congestive heart failure requiring hospitalization or unstable angina).
• Known explanation for the interstitial lung disease, including but not limited to radiation, drug toxicity, sarcoidosis, pneumoconiosis.
• Clinical diagnosis of any connective tissue disease, including but not limited to scleroderma, polymyositis/dermatomyositis, and rheumatoid arthritis.
• Expected to receive a lung transplant within 4 months from enrollment.
• Pregnant women.

Eligibility last updated 9/27/21. Questions regarding updates should be directed to the study team contact.